Related Experiment Video
Updated: May 13, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Anderson-Fabry disease in children
Simona Sestito1, Ferdinando Ceravolo, Daniela Concolino
1Department of Pediatrics, University Magna Graecia of Catanzaro, "Pugliese-Ciaccio" Hospital, viale Pio X, 88100 Catanzaro, Italy. dconcolino@unicz.it.
Pediatric Anderson Fabry Disease (AFD) presents early with diverse symptoms, impacting quality of life. Enzyme replacement therapy (ERT) shows promise, but optimal timing for initiating treatment in children requires further research.
Area of Science:
- Pediatric Nephrology
- Rare Diseases
- Metabolic Disorders
Background:
- Anderson Fabry Disease (AFD) often manifests in childhood with neurological, gastrointestinal, and ocular symptoms.
- Early signs of major organ damage are also observed in pediatric AFD patients.
- Current diagnostic challenges stem from the unspecific nature of early AFD symptoms.
Purpose of the Study:
- To review the current understanding of pediatric Anderson Fabry Disease.
- To highlight the clinical manifestations and diagnostic considerations in children.
- To discuss the current evidence and unresolved questions regarding enzyme replacement therapy (ERT) initiation in pediatric AFD.
Main Methods:
- Literature review of studies on pediatric AFD.
- Analysis of clinical trial data for enzyme replacement therapy (agalsidase alfa and beta) in children.
- Synthesis of current knowledge on AFD pathogenesis, clinical presentation, and treatment.
Main Results:
- Pediatric AFD exhibits a distinct phenotype with earlier onset in males.
- Both agalsidase alfa and agalsidase beta have demonstrated clinical and pharmacodynamic effects in children.
- Differences in safety profiles and administration exist between the two ERT formulations.
Conclusions:
- Early diagnosis and intervention in pediatric AFD are crucial.
- While ERT is effective, the optimal timing for initiating treatment to prevent irreversible organ damage remains undetermined.
- Further controlled trials are necessary to establish the benefits of early ERT initiation and optimal treatment timing in children with AFD.
More Related Videos
06:48Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome
Published on: March 23, 2022
05:56Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
Published on: August 29, 2025
Related Concept Videos
Lysosomal Hydrolases
Rheumatic Heart Disease I: Introduction
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Smooth Endoplasmic Reticulum
The ER provides optimal conditions for synthesizing steroid hormones and lipids, such as phospholipids and triglycerides. Traditionally, lipid metabolism was considered to be a smooth ER function. However, there is no direct evidence to prove that rough ER is completely excluded from lipid...
Inborn Errors of Metabolism
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...